Crossmark

Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy

Crossref DOI link: https://doi.org/10.1186/s40425-018-0496-6

Published Online: 2019-01-16

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bartee, Mee Y.

Dryja, Parker C.

Bartee, Eric http://orcid.org/0000-0003-1793-446X
Funding

Funding for this research was provided by:

National Institute of Allergy and Infectious Diseases (1K22AI095372)

National Cancer Institute (1R01CA194090)

American Cancer Society (RSG-17-047-01-MPC)

Hollings Cancer Center, Medical University of South Carolina (P30 CA138313)
More Information

Article History

Received: 22 August 2018

Accepted: 26 December 2018

First Online: 16 January 2019

Ethics approval and consent to participate

: Not Applicable.

: Not Applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.